Search
We have quantified the relative influence of perinatal risk factors associated with skin infection hospitalisations in WA children
Staphylococcus aureus bacteremia (SAB) is the most common cause of childhood sepsis contributing to pediatric intensive care unit admission. The cost of adult SAB hospitalization is well described globally, but limited costing information is available for children. To bridge this knowledge gap, we investigated the cost of hospitalization in children with SAB in Australia.
Aboriginal families across Western Australia are being equipped with the knowledge to take early action against potentially life-threatening skin infections thanks to the launch of a Strong Skin phone app.
The Kids Research Institute Australia has two researchers and an innovative science engagement initiative as finalists in the 2017 Premier’s Science Awards.
A Northern Territory-based research project investigating alternative and more practical treatments for skin sores (impetigo) benefiting children worldwide.
Three researchers from The Kids Research Institute Australia were recognised as being among Western Australia’s brightest and most innovative scientific minds at last night’s 24th Premier's Science Awards.
A children’s book – written by community, for community – has been launched in Western Australia’s south-west to help children and families understand more about one of the most common inflammatory skin conditions in children.
The The Kids Skin Health team has a busy six weeks ahead - visiting nine communities throughout the Kimberley region of WA as part of the first school surveillance activities for the SToP Trial.
A year after launching the first National Healthy Skin Guideline to address record rates of skin infections in Australia’s Indigenous communities, The Kids Research Institute Australia has released a new resource as part of the guideline.
The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is a multifactorial Bayesian adaptive platform trial that aims to improve the way that S. aureus bloodstream infection, a globally common and severe infectious disease, is treated. In a world first, the SNAP trial will simultaneously investigate the effects of multiple intervention modalities within multiple groups of participants with different forms of S. aureus bloodstream infection.